Cantor Fitzgerald analyst Josh Schimmer initiated coverage of BridgeBio with an Overweight rating and $50 price target. The analyst sees a path to over $5B in peaks for BridgeBio between acoramidis, encaleret and infigratinib. This could ultimately support a valuation greater than $25B versus the current $4.5B, making BridgeBio one of the best names to own in biotech, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio reports inducement grants under Nasdaq listing rule
- BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- BridgeBio announces proof-of-concept Phase 2b data on encaleret
- BridgeBio has positive readthrough from Alnylam’s CRL, says BofA
